__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

This page describes patient-reported outcome measures in urticaria.

Monthly

The UCT covers the following 4 domains:

ion-patient_outcome-measures

  • Validated and specifically designed for chronic urticaria
  • Self-administered, retrospective (past 4 weeks) 4-item questionnaire
  • Each answer is scored ranging from 0 to 4
  • The summed score ranges from 0: no control to 16: full control 

 

csu-clinical-differences-diagram 

Daily

A method for assessing disease severity

  • Tools are available for angioedema-only patients2
  • Patient scores their number of hives (0 to 3) and pruritus severity (0 to 3) each day for 7 days2
  • Maximum weekly score is 42 – a higher score corresponds to more severe disease2
  • Severe CSU has a UAS7 score of 28–423

*Included in the NICE guidance as an example of objective assessment of disease severity.
Scoring from 0 (none) to 3 (intense).

 

csu-disease-severity-chart

Weekly

The DLQI is a simple, validated questionnaire used to evaluate health-related quality of life in patients with skin diseases.

  • It consists of 10 questions comprising 6 domains:

 

csu-weekly-symptoms-icon

 

Symptoms and feelings

csu-weekly-activities

 

Daily activities

csu-weekly-relationships

 

Personal relationships

 

 
csu-weekly-leisure

 

Leisure

csu-weekly-work-school

 

Work and school

csu-weekly-treatment

 

Treatment

 

 
  • The effect of the disease on each domain is scored from 0 (not at all) to 3 (very much) for each question, giving a total score of between 0 and 30
  • Higher DLQI score corresponds to greater impairment on quality of life 

csu-patient-outcomes-resource-thumb

PATIENT-REPORTED OUTCOMES RESOURCE

The patient-reported outcomes guideline presents patient-reported outcomes for healthcare professionals to use with patients with CSU; these outcomes include the UCT, UAS7 and DLQI.

View

 

As part of our mission to be as environmentally friendly as possible, we provide our resources in electronic form.

These materials should not be printed by healthcare professionals.

CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; UAS7, urticaria activity score at seven days; UCT, urticaria control test.

References

  1. Moestrup K, et al. Int J Dermatol 2017; 56:1342–1348.
  2. Zuberbier T, et al. Allergy 2014; 69:868–887.
  3. Stull D, et al. EAACI 2014, abstract 826.
  4. Finlay AY, et al. Clin Exp Dermatol 1994;19(3):210–216. 
Rate this content: 
No votes yet
UK | October 2021 | 146364
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]